GRAL
GRAIL’s growth story is still very much alive
GRAIL rolled out its second-quarter 2026 results on August 5th, and the headline is pretty simple: more people are using Galleri, and the business is getting bigger along with it. Test volume climbed 35% year over year to more than 61,000, while Galleri revenue increased 24% to $42.6 million.
That’s the kind of update growth investors like to see — not because the company has magically turned into a cash fountain, but because the core product is showing real traction. For the first half of the year, volume was up 42% and revenue grew 30%, which suggests the engine is still gaining speed instead of sputtering out.
Not just numbers, but a little science too
GRAIL also said NHS-Galleri and PATHFINDER 2 study results presented at the 2026 ASCO Annual Meeting showed consistent performance and clinical utility for Galleri. Translation: the company is trying to prove this isn’t just a nice-sounding blood test, but a tool doctors may actually trust in the wild.
The catch? Growth isn't free
The other thing to notice is the $110 million equity financing with Samsung. That’s a helpful cash boost, sure, but it also means the company is buying time the old-fashioned way: by tapping the market. If you’re a shareholder, that’s the classic startup tradeoff — more fuel in the tank, but your slice of the pie can get a little thinner.
Big picture: GRAIL is still pushing the “cancer detection at scale” thesis, and this quarter gave bulls some fresh ammo. The question now is whether the company can keep growing Galleri fast enough to justify the fundraising treadmill.